Osteoarthritis, knee
Therapeutic area
Rheumatology
Rare disease
No
- Definition
- Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Osteoarthritis, knee
- Alternative names
- osteoarthritis, knee
- Therapeutic area
- Rheumatology
- Disease mechanisms
- Inflammatory
- All therapeutic areas
- Rheumatology
- Severity
- Mild
- MONDO ID
- MONDO:0005416
- Parent condition
- MONDO:0005178
Related records
Broader conditions (12)
- Arthritic joint disease
- Arthropathy
- Bone disorder
- Bone inflammation disease
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Inflammatory disease
- Musculoskeletal system disorder
- Osteoarthritis
- Skeletal system disorder
Trials (3,162)
- "Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis"
- "CuraMed" and "Curamin" in Osteoarthritis
- "Effectiveness of Mulligan Mobilization Technique and Proprioceptive Exercises Among Patients With Knee Osteoarthritis"
- "Score Infectivity" During Reoperation on Total Hip or Knee Prosthesis
- "The Importance of Adding Fenestration to Ultrasound-Guided Baker's Cyst Aspiration"
- ยง Procaine Periarticular Injections for Pain Reduction in Elderly With Osteoarthritis
- 2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)
- 3-point vs 6-point GNRFA for Chronic KOA
- 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis
- 3D Joint Space Evaluation in Knee Osteoarthritis: The Importance of Weight-bearing and Flexion
- 3D Printing Guides in Total Knee Arthroplasty
- A 12 Week, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee
- A 12-Week Home-Based Electrical Stimulation Program for Strength in Adults With Knee Osteoarthritis
- A 2-year, European Multicentre Study to Describe, Validate, and Predict Phenotypes of Knee Osteoarthritis
- A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis
- A Better Way to Decrease Knee Swelling in Patients With Knee Osteoarthritis
- A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee"
- A Biologic Joint Replacement Strategy for Knee Trauma and Post-Traumatic Osteoarthritis
- A Biomechanical Exercise Program for Knee OA
- A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
Drugs in development (127)
- Acetaminophen Phase 3
- Adalimumab Phase 2
- ADL-5747 Phase 2
- ADL-5859 Phase 2
- ARRY-797 Phase 2
- Aspartyl-alanyl-diketopiperazine Phase 3
- Astaxanthin Phase 2
- Atorvastatin Phase 2
- Balicatib Phase 2
- Bupivacaine Phase 3
- Bupivacaine hydrochloride Phase 3
- Buprenorphine Phase 3
- Canakinumab Phase 2
- Cannabidiol Phase 3
- Cannabinol Phase 2
- Capsaicin Phase 3
- Carbacyclic phosphatidic acid Phase 1
- Cebranopadol Phase 2
- Celecoxib Phase 3
- Chondroitin sulfate sodium Phase 3
Other linked drugs (7)
- Autologous adipose-derived stromal vascular fraction
- Chondroitin sulfate
- Denosumab
- Etanercept
- Ketamine
- Magnesium sulfate
- Strontium ranelate